MUC16 and ovarian cancer: These results indicate that CR may not fully supersede CAR in tumor killing, but CAR- and CR-co-expressing T cells exhibit a significantly enhanced ability to target ovarian cancer, which indicates that CR and CAR exert a synergistic effect on CA125-expressing ovarian cancer cells.